By investing in the Lupus Foundation of America, your donation, no matter the gift size, is being put to work. Read more from Donna Grogan, Vice President of Development and Fundraising.
Kim Cantor, Lupus Foundation of America’s Senior Director of Public Policy and Government Relations, discusses the Foundation’s Medicare for Patients RX (MAPRx) Coalition
Dr. Gary Gilkeson of the Medical University of South Carolina discusses his Lupus Foundation of America funded study on the potential use of human mesenchymal stem cells as a therapy for lupus.
In her Expert Column, Dr. Joan T. Merrill, Medical Director, explains why antimalarial medicines are now used to treat lupus.
A new study that analyzed lupus treatment data from past global clinical trials suggests that when testing new drugs in combination with other background therapies, clinical trials should be designed to account for the effects that initial disease activity and background drug treatment have been shown to have on planned endpoints, like response and flare rates.
The outlook for positive pregnancy outcomes for women with lupus remains bright, but data obtained from a large insurance claims database highlights the need for specific education and counseling to pregnant women with lupus as well as close collaboration between the rheumatologist and the obstetrician throughout the pregnancy.
Although the overall risk is small, children born to mothers with lupus may have a higher risk of autism spectrum disorders than children born to mothers without the disease, according to the results of a study presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.
International knowledge healthcare provider BMJ and the Lupus Foundation of America have announced that they have joined forces to publish the first open access journal dedicated to lupus. Lupus Science & Medicine™ will offer timely global access to the latest scientific advances in lupus.